Allergan investors, rooting for a breakup, cheer rapastinel's phase 3 flop

A major Allergan pipeline candidate may have failed phase 3 on Wednesday, but investors cheered the news. The reason? They’re anticipating extreme measures—namely, a company split-up that would make the most of its aesthetics business.